Sanroxa

Sanroxa

oxaliplatin

Manufacturer:

Sanbe
Concise Prescribing Info
Contents
Oxaliplatin
Indications/Uses
Combination w/ 5-FU & folinic acid as adjuvant treatment of stage III (Duke's C) colon cancer after complete resection of primary tumor. Treatment of metastatic CRC.
Dosage/Direction for Use
IV Adjuvant treatment 85 mg/m2 repated every 2 wk for 12 cycles for 6 mth. Metastatic CRC 85 mg/m2 2 wkly. Administer for 2-6 hr as IV diluted infusion in 250-500 mL of 5% glucose.
Contraindications
Hypersensitivity. Myelosuppression (neutrophils <2 x 109/L) before the 1st treatment cycle; sensory peripheral sensitive neuropathy w/ functional impairment prior to the 1st cycle of treatment; severe renal insufficiency (CrCl <30 mL/min). Lactation.
Special Precautions
Diarrhea, nausea, vomiting, mucositis, neutropenia, thrombocytopenia & neurological (acute & dose cumulative sensory peripheral neuropathy).
Drug Interactions
5-FU, erythromycin, salicylates, granisetron, paclitaxel & Na valproate.
MIMS Class
Cytotoxic Chemotherapy
ATC Classification
L01XA03 - oxaliplatin ; Belongs to the class of platinum-containing antineoplastic agents. Used in the treatment of cancer.
Presentation/Packing
Form
Sanroxa inj 100 mg/20 mL
Packing/Price
1's (Rp4,444,150/boks)
Form
Sanroxa inj 50 mg/10 mL
Packing/Price
1's (Rp2,229,400/boks)
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in